BUY Zydus Lifesciences Limited — Arun Kumar Mantri

Entry₹1,109.2Inferred
Target₹1,145
Total upside +3.23% (call closed)
Stop loss₹1,090-1.73% risk
Exit₹1,09015 Jun 2026, 12:50 pm
Stop-loss hit-1.73%

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

As of 25 Oct, 10:50 pm IST
2 supporting1 neutral0 opposing
Supports the BUY call (2)

3 other SEBI-registered advisors have active swing BUY calls on this stock, all issued in the last 14 days

Advisor consensus · same horizon·10 Jun · 5d ago

Zydus Lifesciences Limited's New Drug Application (NDA) for Saroglitazar to treat Primary Biliary Cholangitis (PBC) has been granted Priority Review by the US FDA.

NSE · Press Release·28 May · 2w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.